Se vende con distintos nombres comerciales, entre ellos Ozempic , Rybelsus, Wegovy y Dutide
Combination-therapy models: Evaluating interactions with GLP-1 receptor agonists (e.g., semaglutide) to study additive or complementary effects on appetite and metabolism
IL-1R, IL-1, IL-6R, IL-6 a , IL-2, IL-10, IL-15, IL-17, IL-17R, IL-18, IL-23, interleukin (IL)-1 receptor, -1 beta, -6 receptor, -6 antibody, -2, -10, -15, -17, -17 receptor, -18, -23, respectively
The Bridge currently covers the following GLP-1 medications when prescribed for weight management: Wegovy (injection and pills) Zepbound (KwikPen only) Foundayo (pills) Important note on Zepbound: Only the Zepbound KwikPen is covered under the Bridge